Posting of Annual Report & Notice of AGM

EKF Diagnostics Holdings plc, the AIM listed point-of-care, central laboratory and molecular diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2014, the Notice of the Annual General Meeting and a Form of Proxy have been posted to shareholders.

The AGM is to be held on 19 May 2015 at the offices of Panmure Gordon, One New Change, London EC4M 9AF at 2pm.

A copy of the 2014 Annual Report and Accounts and other documents are available on this website.

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

TR-1: Standard form for notification of major holdings

Notification of major holdings.

2017 Final Results

EKF Diagnostics announces its final results for the year ended 31 December 2017.

Notice of results - Investor results presentation

EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.

Trading update

EKF Diagnostics provides shareholders with the following update on current trading.

Total voting rights

As at 29 December 2017, the Company's total issued share capital consists of 457,554,636 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.